---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-23-000404"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2023-01-12T23:59:59+00:00"
generated_at: "2026-06-20T15:55:22.305212+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Precigen reports pipeline progress and R&D Day for PRGN-2012 data on Jan 24, 2023

## Summary
- PRGN-2012 Phase 2 enrollment rapid; 20 patients enrolled; R&D Day Jan 24 to share Phase 1 data.
- PRGN-2009 Phase 2 monotherapy arm near full enrollment: 19 of 20 patients; interim data expected H2 2023.
- PRGN-3006 in AML: Phase 1 dose escalation data presented at ASH; Phase 1b expansion includes Mayo Clinic; first repeat dose cleared.
- PRGN-3005 in ovarian cancer: Phase 1 dose escalation completed; first repeat dose given; expansion enrollment ongoing.
- PRGN-3007 (next-gen UltraCAR-T) trial open for enrollment; first patient dosing expected Q1 2023.

## SEC filing metadata
- accession: 0000950103-23-000404
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2023-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010323000404/0000950103-23-000404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010323000404/dp186955_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-23-000404
- JSON: https://secwatch.observer/filing/0000950103-23-000404.json
- Plain text: https://secwatch.observer/filing/0000950103-23-000404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.